EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 732 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate May 4, 2021 Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases July 10, 2024 Daughter Donates Hair to Mother After She Was Diagnosed with Stage... March 3, 2021 Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in... February 27, 2023 Load more HOT NEWS Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated... Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active... Severe mental illness linked to low attendance at cancer screening
